Here are four things to know:
1. OsteoArthritis will use Gensco’s patented Transdermal products as an additional option to demonstrate improved patient outcomes.
2. The product will also add economic value of treating pain with transdermal technology.
3. The research collaboration will work on providing a non-narcotic pain control option for patients.
4. Carlos Alfaras, president and CEO of Gensco Labs, is confident the partnership will yield successful results due to OA Center of America’s expertise in treating patients with osteoarthritis and musculoskeletal pain.
For more on practice management:
5 things to know about Lemak Health opening a new sports medicine clnic
5 areas of focus to improve your patient acquisition through online marketing
Second opinions often result in dianosis or treatment changes — 5 key points
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.